These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 19952991)

  • 61. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy.
    Wei Q; Zhang T; Jiang R; Chang Q; Zhang Y; Huang X; Gao X; Jin H; Xu G
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5783-5791. PubMed ID: 29117316
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Levels of vascular endothelial growth factor and pigment epithelium-derived factor in eyes before and after intravitreal injection of bevacizumab.
    Matsuyama K; Ogata N; Jo N; Shima C; Matsuoka M; Matsumura M
    Jpn J Ophthalmol; 2009 May; 53(3):243-8. PubMed ID: 19484443
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab.
    Nonobe NI; Kachi S; Kondo M; Takai Y; Takemoto K; Nakayama A; Hayakawa M; Terasaki H
    Retina; 2009 May; 29(5):579-85. PubMed ID: 19430279
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes.
    Inan UU; Avci B; Kusbeci T; Kaderli B; Avci R; Temel SG
    Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1773-81. PubMed ID: 17389511
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Intravitreal bevacizumab in active progressive proliferative diabetic retinopathy.
    Moradian S; Ahmadieh H; Malihi M; Soheilian M; Dehghan MH; Azarmina M
    Graefes Arch Clin Exp Ophthalmol; 2008 Dec; 246(12):1699-705. PubMed ID: 18696095
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Panretinal photocoagulation versus PRP plus intravitreal bevacizumab for high-risk proliferative diabetic retinopathy (IBeHi study).
    Tonello M; Costa RA; Almeida FP; Barbosa JC; Scott IU; Jorge R
    Acta Ophthalmol; 2008 Jun; 86(4):385-9. PubMed ID: 17995982
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Effect of an intravitreal injection of bevacizumab on the expression of VEGF and CD34 in the retina of diabetic rats.
    Ma J; Zhu T; Tang X; Ye P; Zhang Z
    Clin Exp Ophthalmol; 2010 Dec; 38(9):875-84. PubMed ID: 20653693
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vitrectomy with or without preoperative intravitreal bevacizumab for proliferative diabetic retinopathy: a meta-analysis of randomized controlled trials.
    Zhang ZH; Liu HY; Hernandez-Da Mota SE; Romano MR; Falavarjani KG; Ahmadieh H; Xu X; Liu K
    Am J Ophthalmol; 2013 Jul; 156(1):106-115.e2. PubMed ID: 23791371
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Structural consequences after intravitreal bevacizumab injection without increasing apoptotic cell death in a retinopathy of prematurity mouse model.
    Akkoyun I; Karabay G; Haberal N; Dagdeviren A; Yilmaz G; Oto S; Erkanli L; Akova YA
    Acta Ophthalmol; 2012 Sep; 90(6):564-70. PubMed ID: 20698831
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Intravitreal bevacizumab (Avastin) for primary treatment of diabetic macular oedema.
    Ozkiriş A
    Eye (Lond); 2009 Mar; 23(3):616-20. PubMed ID: 18437176
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab.
    Funk M; Schmidinger G; Maar N; Bolz M; Benesch T; Zlabinger GJ; Schmidt-Erfurth UM
    Retina; 2010 Oct; 30(9):1412-9. PubMed ID: 20711086
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Vitreous web after pars plana vitrectomy and bevacizumab with fluid-air exchange.
    Chiang A; Reddy S; Tsui I; Hubschman JP
    Semin Ophthalmol; 2011 Jan; 26(1):25-7. PubMed ID: 21275601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.
    Gupta A; Bansal R; Gupta V; Dogra MR
    Int Ophthalmol; 2012 Apr; 32(2):135-44. PubMed ID: 22450558
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study.
    Cheema RA; Al-Mubarak MM; Amin YM; Cheema MA
    J Cataract Refract Surg; 2009 Jan; 35(1):18-25. PubMed ID: 19101420
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab.
    Matsuyama K; Ogata N; Matsuoka M; Wada M; Takahashi K; Nishimura T
    Br J Ophthalmol; 2010 Sep; 94(9):1215-8. PubMed ID: 20538658
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Analysis of the effect of intravitreal bevacizumab injection on diabetic macular edema after cataract surgery.
    Takamura Y; Kubo E; Akagi Y
    Ophthalmology; 2009 Jun; 116(6):1151-7. PubMed ID: 19376589
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Fang X; Sakaguchi H; Gomi F; Oshima Y; Sawa M; Tsujikawa M; Ikuno Y; Kamei M; Kusaka S; Tano Y
    Acta Ophthalmol; 2008 Nov; 86(7):800-5. PubMed ID: 18547274
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy and safety of one intravitreal injection of bevacizumab in diabetic macular oedema.
    Kumar V; Ghosh B; Raina UK; Goel N
    Acta Ophthalmol; 2010 Mar; 88(2):e3; author reply e4. PubMed ID: 19549100
    [No Abstract]   [Full Text] [Related]  

  • 79. The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
    Yan Y; Zhu L; Hong L; Deng J; Song Y; Chen X
    Acta Ophthalmol; 2016 Jun; 94(4):358-64. PubMed ID: 26285163
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of the clinical efficacy of intravitreal bevacizumab in the treatment of iris neovascularization caused by proliferative diabetic retinopathy.
    Jiang Y; Liang X; Li X; Tao Y; Wang K
    Acta Ophthalmol; 2009 Nov; 87(7):736-40. PubMed ID: 18803622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.